Jonathan A. Chapman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan A. Chapman has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Christopher James Stewart
Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK
6 shared publications - Janet Elizabeth Berrington
Newcastle Neonatal Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
4 shared publications - Christopher Andrew Lamb
Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK
3 shared publications - Lindsay J. Hall
University of Birmingham
3 shared publications - Nicholas David Embleton
Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
3 shared publications - Robert K. Poole
Department of Molecular Biology and Biotechnology, The University of Sheffield, Sheffield, S10 2TN, UK
3 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Microbiome and immune development in preterm infants receiving powdered human milk‐based fortification from the PUFFIN trial
Objective: To determine the impact of powdered human milk‐based fortification (PHMF) compared to powdered bovine milk‐based fortification on gut microbiome and inflammation in preterm infants. Methods: Mechanistic study within randomised controlled trial in infants p = 0.04; 25.7% at D21, p = 0.007). Stool but not urine sIgA was higher in PHMF recipients. Whilst fortifier type was not associated with IRPs from D7 to D21, NICU site impacted IRPs. Conclusions: Fortifier type did not have a large impact on microbiota or IRPs but stool sIgA was higher in PHMF recipients. An association between NICU site and other outcomes was observed. Trial Registration: ClinicalTrials.gov identifier: The Preterm milk fortification in neonates (PUFFIN) study was prospectively registered ISRCTN 22484792.
- 10 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Open AccessMicrobiome and immune development in preterm infants receiving powdered human milk‐based fortification from the PUFFIN trial
Objective: To determine the impact of powdered human milk‐based fortification (PHMF) compared to powdered bovine milk‐based fortification on gut microbiome and inflammation in preterm infants. Methods: Mechanistic study within randomised controlled trial in infants p = 0.04; 25.7% at D21, p = 0.007). Stool but not urine sIgA was higher in PHMF recipients. Whilst fortifier type was not associated with IRPs from D7 to D21, NICU site impacted IRPs. Conclusions: Fortifier type did not have a large impact on microbiota or IRPs but stool sIgA was higher in PHMF recipients. An association between NICU site and other outcomes was observed. Trial Registration: ClinicalTrials.gov identifier: The Preterm milk fortification in neonates (PUFFIN) study was prospectively registered ISRCTN 22484792.
- Top Cited PapersOpen Access
- 16 March 2026
- Published by Springer Nature in Nature Microbiology
- Vol. 11 (4) , 940-959
Clostridia from preterm infants metabolize human milk oligosaccharides to suppress pathobionts and modulate intestinal function in organoids
Infant gut microbiome development is strongly impacted by breastmilk and human milk oligosaccharides (HMOs), which can protect preterm infants against pathologies including necrotizing enterocolitis. HMO metabolism in bifidobacteria is well characterized and linked to health outcomes, but the scope of HMO-utilizing species remains unclear. Here, using a combination of genomics, proteomics and metabolomics, we show that Clostridium species isolated from preterm infants (born at Clostridium perfringens lacking the toxin perfringolysin O (PfoA), metabolized HMOs. Clostridium species produced beneficial metabolites including short-chain fatty acids and tryptophan catabolites at higher quantities than Bifidobacterium species in vitro. Cell-free supernatant from C. perfringens was non-toxic to colonic cell lines, promoted the growth of commensal bifidobacteria and inhibited growth of pathobionts isolated from the preterm infant gut in vitro. It also suppressed inflammation in preterm-derived intestinal organoids. These findings expand our understanding of HMO-metabolizing microbes and suggest that pfoA − C. perfringens strains could contribute to healthy infant gut development.
- 16 March 2026
- Published by Springer Nature in Nature Microbiology
- Vol. 11 (4) , 940-959
Top Cited PapersOpen AccessClostridia from preterm infants metabolize human milk oligosaccharides to suppress pathobionts and modulate intestinal function in organoids
Infant gut microbiome development is strongly impacted by breastmilk and human milk oligosaccharides (HMOs), which can protect preterm infants against pathologies including necrotizing enterocolitis. HMO metabolism in bifidobacteria is well characterized and linked to health outcomes, but the scope of HMO-utilizing species remains unclear. Here, using a combination of genomics, proteomics and metabolomics, we show that Clostridium species isolated from preterm infants (born at Clostridium perfringens lacking the toxin perfringolysin O (PfoA), metabolized HMOs. Clostridium species produced beneficial metabolites including short-chain fatty acids and tryptophan catabolites at higher quantities than Bifidobacterium species in vitro. Cell-free supernatant from C. perfringens was non-toxic to colonic cell lines, promoted the growth of commensal bifidobacteria and inhibited growth of pathobionts isolated from the preterm infant gut in vitro. It also suppressed inflammation in preterm-derived intestinal organoids. These findings expand our understanding of HMO-metabolizing microbes and suggest that pfoA − C. perfringens strains could contribute to healthy infant gut development.
- Open Access
Staphylococcus haemolyticus Population Genomics Provides Insights into Pathogenicity and Commensalism
Staphylococcus haemolyticus is a common commensal bacterium but also an opportunistic pathogen, frequently implicated in bacteraemia and sepsis in preterm neonates and immunocompromised patients. Despite its clinical relevance, relatively little is known about the population structure of S. haemolyticus and how this relates to its ability to colonise humans or cause disease. In this study, we analysed commensal and clinical strains isolated from neonates and adults from 20 countries between 1957 - 2022. Whole genome sequencing of these isolates, combined with publicly available data, generated a comprehensive dataset of 986 genomes. This enabled us to characterise the species population structure and track the distribution of antimicrobial resistance (AMR) and virulence determinants. Our analysis revealed a highly diverse genome structure, with multiple phylogenetic groups showing distinct associations with commensalism or pathogenicity. We observed extensive variation in mobile genetic elements, prophages, and AMR genes, alongside increased carriage of plasmids and AMR genes over time. Furthermore, genes lined to metal homeostasis, detoxification, and oxidative stress tolerance were differently abundant between commensal and clinical isolates. This work provides the most detailed view to date of S. haemolyticus diversity, its evolutionary dynamics, and the genetic factors that may underpin the transition from commensal to pathogen.
Open AccessStaphylococcus haemolyticus Population Genomics Provides Insights into Pathogenicity and Commensalism
Staphylococcus haemolyticus is a common commensal bacterium but also an opportunistic pathogen, frequently implicated in bacteraemia and sepsis in preterm neonates and immunocompromised patients. Despite its clinical relevance, relatively little is known about the population structure of S. haemolyticus and how this relates to its ability to colonise humans or cause disease. In this study, we analysed commensal and clinical strains isolated from neonates and adults from 20 countries between 1957 - 2022. Whole genome sequencing of these isolates, combined with publicly available data, generated a comprehensive dataset of 986 genomes. This enabled us to characterise the species population structure and track the distribution of antimicrobial resistance (AMR) and virulence determinants. Our analysis revealed a highly diverse genome structure, with multiple phylogenetic groups showing distinct associations with commensalism or pathogenicity. We observed extensive variation in mobile genetic elements, prophages, and AMR genes, alongside increased carriage of plasmids and AMR genes over time. Furthermore, genes lined to metal homeostasis, detoxification, and oxidative stress tolerance were differently abundant between commensal and clinical isolates. This work provides the most detailed view to date of S. haemolyticus diversity, its evolutionary dynamics, and the genetic factors that may underpin the transition from commensal to pathogen.
- 16 May 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (6) , 1263-1266
Opportunities for microbiome-based therapeutics in preterm infants
- 16 May 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (6) , 1263-1266
Opportunities for microbiome-based therapeutics in preterm infants
- Open Access
Human milk oligosaccharide metabolism by Clostridium species suppresses inflammation and pathogen growth
Gut microbiome development is strongly impacted by breastmilk and human milk oligosaccharides (HMOs), with short- and long-term health implications. HMO metabolism is best characterised within bifidobacteria, but the full range of other HMO-utilising species remains unknown. This study examined HMO-utilising bacteria that colonise preterm infants (born Clostridium perfringens , and three other Clostridium species, metabolise HMOs, producing short chain fatty acids, tryptophan catabolites, and other metabolites known to improve host health. C. perfringens inhibited pathobiont growth and supressed inflammation in preterm-derived intestinal organoids. These findings suggest a previously unrecognised role for C. perfringens , specifically those lacking the perfringolysin O gene, in promoting healthy gut development during infancy.
Open AccessHuman milk oligosaccharide metabolism by Clostridium species suppresses inflammation and pathogen growth
Gut microbiome development is strongly impacted by breastmilk and human milk oligosaccharides (HMOs), with short- and long-term health implications. HMO metabolism is best characterised within bifidobacteria, but the full range of other HMO-utilising species remains unknown. This study examined HMO-utilising bacteria that colonise preterm infants (born Clostridium perfringens , and three other Clostridium species, metabolise HMOs, producing short chain fatty acids, tryptophan catabolites, and other metabolites known to improve host health. C. perfringens inhibited pathobiont growth and supressed inflammation in preterm-derived intestinal organoids. These findings suggest a previously unrecognised role for C. perfringens , specifically those lacking the perfringolysin O gene, in promoting healthy gut development during infancy.
- Open Access
- 26 February 2023
- Published by Taylor & Francis in Gut Microbes
- Vol. 15 (1) , 2183687
Methodological challenges in neonatal microbiome research
Following microbial colonization at birth, the gut microbiome plays a vital role in the healthy development of human neonates and impacts both health and disease in later life. Understanding the development of the neonatal gut microbiome and how it interacts with the neonatal host are therefore important areas of study. However, research within this field must address a range of specific challenges that impact the design and implementation of research methods. If not considered ahead of time, these challenges have the potential to introduce biases into studies, negatively affecting the relevance, reproducibility, and impact of any findings. This review outlines the nature of these challenges and points to current and future solutions, as outlined in the literature, to assist researchers in the early stages of study design.
- 26 February 2023
- Published by Taylor & Francis in Gut Microbes
- Vol. 15 (1) , 2183687
Open AccessMethodological challenges in neonatal microbiome research
Following microbial colonization at birth, the gut microbiome plays a vital role in the healthy development of human neonates and impacts both health and disease in later life. Understanding the development of the neonatal gut microbiome and how it interacts with the neonatal host are therefore important areas of study. However, research within this field must address a range of specific challenges that impact the design and implementation of research methods. If not considered ahead of time, these challenges have the potential to introduce biases into studies, negatively affecting the relevance, reproducibility, and impact of any findings. This review outlines the nature of these challenges and points to current and future solutions, as outlined in the literature, to assist researchers in the early stages of study design.
- Open Access
- 5 June 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (6) , 915
‘Carbon-Monoxide-Releasing Molecule-2 (CORM-2)’ Is a Misnomer: Ruthenium Toxicity, Not CO Release, Accounts for Its Antimicrobial Effects
Carbon monoxide (CO)-releasing molecules (CORMs) are used to deliver CO, a biological ‘gasotransmitter’, in biological chemistry and biomedicine. CORMs kill bacteria in culture and in animal models, but are reportedly benign towards mammalian cells. CORM-2 (tricarbonyldichlororuthenium(II) dimer, Ru2Cl4(CO)6), the first widely used and commercially available CORM, displays numerous pharmacological, biochemical and microbiological activities, generally attributed to CO release. Here, we investigate the basis of its potent antibacterial activity against Escherichia coli and demonstrate, using three globin CO sensors, that CORM-2 releases negligible CO (Kd 3 μM; His, Kd 130 μM) as determined by 1H-NMR. Glutathione is proposed to be an important intracellular target of CORM-2, with CORM-2 having a much higher affinity for reduced glutathione (GSH) than oxidised glutathione (GSSG) (GSH, Kd 2 μM; GSSG, Kd 25,000 μM). The toxicity of low, but potent, levels (15 μM) of CORM-2 was accompanied by cell lysis, as judged by the release of cytoplasmic ATP pools. The biological effects of CORM-2 and related CORMs, and the design of biological experiments, must be re-examined in the light of these data.
- 5 June 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (6) , 915
Open Access‘Carbon-Monoxide-Releasing Molecule-2 (CORM-2)’ Is a Misnomer: Ruthenium Toxicity, Not CO Release, Accounts for Its Antimicrobial Effects
Carbon monoxide (CO)-releasing molecules (CORMs) are used to deliver CO, a biological ‘gasotransmitter’, in biological chemistry and biomedicine. CORMs kill bacteria in culture and in animal models, but are reportedly benign towards mammalian cells. CORM-2 (tricarbonyldichlororuthenium(II) dimer, Ru2Cl4(CO)6), the first widely used and commercially available CORM, displays numerous pharmacological, biochemical and microbiological activities, generally attributed to CO release. Here, we investigate the basis of its potent antibacterial activity against Escherichia coli and demonstrate, using three globin CO sensors, that CORM-2 releases negligible CO (Kd 3 μM; His, Kd 130 μM) as determined by 1H-NMR. Glutathione is proposed to be an important intracellular target of CORM-2, with CORM-2 having a much higher affinity for reduced glutathione (GSH) than oxidised glutathione (GSSG) (GSH, Kd 2 μM; GSSG, Kd 25,000 μM). The toxicity of low, but potent, levels (15 μM) of CORM-2 was accompanied by cell lysis, as judged by the release of cytoplasmic ATP pools. The biological effects of CORM-2 and related CORMs, and the design of biological experiments, must be re-examined in the light of these data.
- Open Access
- 1 September 2018
- Published by Elsevier in Redox Biology
- Vol. 18, 114-123
A thiol-reactive Ru(II) ion, not CO release, underlies the potent antimicrobial and cytotoxic properties of CO-releasing molecule-3
- 1 September 2018
- Published by Elsevier in Redox Biology
- Vol. 18, 114-123
Open AccessA thiol-reactive Ru(II) ion, not CO release, underlies the potent antimicrobial and cytotoxic properties of CO-releasing molecule-3